Transcript of conference call with investors & analysts held on May 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Prevest Denpro reported FY25 consolidated revenue of INR 67.09 crores, up 13.6% YoY, with EBITDA margins steady at 38.98% and PAT of INR 18.15 crores (12.51% growth). Q4 was the standout quarter, delivering INR 19.53 crores in revenue (up 21.79% QoQ) and EBITDA margins of 39.03%. Revenue mix remains 60% exports and 40% domestic, with US revenue growing 14% following the launch of subsidiary Axiodent Inc. Management highlighted its push into digital dentistry, including 3D printers, scanners, and bio-based 3D resins, along with plans to launch 4-5 new products in FY26. The company also revealed that earlier post-IPO projections of INR 150 crores revenue were not met due to slower growth (10-13% range), with Oradox contributing only about INR 50 lakhs and 3D resins INR 45-50 lakhs in FY25.
Margins held steady despite cost pressures and management expects profitability to 'enhance considerably' as new digital dentistry products and the US subsidiary scale up, which is positive for earnings stability. However, the failure to meet earlier aggressive growth targets (INR 150 crores projection), small contribution from new product lines, and inability to commit to a higher growth rate (above the current 13%) may temper investor enthusiasm near-term.